Blood: CDK6 is a new potential therapeutic target for acute myeloid leukemia with NUP98 fusion protein
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Fusion proteins associated with nucleoporous protein 98 (NUP98) are repeated in acute myeloid leukemia (AML) and are associated with poor prognosisSo far, insufficient understanding of NUP98-fusion-dependent tumor conversion mechanism has hindered the development of AML targeted therapyresearchers speculated that different NUP98 fusion proteins could deregulate a set of common transcription targets that could be used for targeted therapyTo decipher transcription programs regulated by different NUP98-fusion proteins, the researchers established models of NUP98/NSD1, NUP98/JARID1A, and NUP98/DDX10 expression that can be regulatedthe researchers defined the core set of direct transcription targets for NUP98 fusion proteins by integrating the chromatin occupancy spectrum of NUP98 fusion proteins with the transcription group spectra after acute fusion protein inactivation in vivoCdK6 was highly expressed in mouse and human AML samplesCDK6 deficiency slows the development of NUP98 fusion-driven leukemia, and In addition, NUP98 Fusion AML is sensitive to drug-suppressing CDK6, both in vivo and in vitro, this study shows that CDK6 is a conservative and vital direct target of NUP98 fusion protein, suggesting that CDK4/CDK6 inhibitors can be used as a new and reasonable treatment option for AML patients with NUP98 fusion variants
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
